

OH, Primary Care Program

Nov. 12, 2024

Launch of Ontario Health integrated primary care report

Ontario Health is pleased to share the launch of the *MyPractice* Primary Care Plus (with SAR data) report accessible through ONE ID. This new report integrates the *MyPractice* Primary Care Physician indicators and the Screening Activity Report (SAR) and provides personalized data and suggestions to support physicians in improving care for their patients.

To access this new report, please log in to eReport the using your ONE ID account. See steps below:

1. Navigate to the [eReport](#) portal
2. Click on the ONE ID login option, and enter your login ID ([firstname.lastname@ONEID.on.ca](#)) and password
3. Select the MyPractice PC Plus SAR tab on eReport to view the report
- 4.

With the release of the *MyPractice* Primary Care Plus (with SAR data), physicians can expect the following benefits:

- *MyPractice* Primary Care Physician indicators and SAR data available in one place through ONE ID, making it easier to access information.
 - All future refreshes of the *MyPractice* Primary Care Physician Report will be available through ONE ID and not sent as a PDF via email.
 - Physicians without ONE ID should register using this [Registration guide](#).
- New and simplified access using a single sign-on button for the eReport platform in electronic medical records (EMRs).
- Improved data visualization capabilities through an updated platform to help you gain insights on areas of excellences and areas for improvement.
- Delegate access to the MyPractice Primary Care Physician indicators so that office staff can help you with planning care initiatives.

Learn more

To support you in navigating this transition, Ontario Health is offering live training webinars. Please register for an upcoming training webinar by clicking [here](#).

Frequently asked questions, registration instructions and learning modules are available [here](#).

2. Biosimilar Update

Effective November 29, 2024, Ontario will add two additional biologic drugs to the biosimilar policy: Prolia® (denosumab) and Xgeva® (denosumab). This transition period will last for 9 months, concluding on August 29, 2025.

Biosimilar versions of Prolia® and Xgeva® (which are Jubbonti® and Wyost® respectively) were listed on the Ontario Drug Benefit (ODB) Formulary as Limited Use benefits in August 2024. Recipients who are treatment naïve to Prolia® and Xgeva® will only receive coverage for the biosimilar versions. All treatment established patients are required to transition to the biosimilar version by August 29, 2025, to maintain ODB coverage.

The Ministry will provide exemptions to ensure that unique and individual patient situations experienced with switching to the biosimilar can be evaluated:

- An LU code will be provided for palliative patients on Prolia®
- Palliative requests for Xgeva® can be submitted to the Exceptional Access Program (EAP) through SADIE or by fax
- All medically necessary exemptions to continue treatment with Prolia® and Xgeva® will need to be obtained on a case-by-case basis through the EAP. Prescribers must ensure that sufficient and appropriate evidence is provided to support the request.